Search results
Results from the WOW.Com Content Network
Participants in a clinical trial of an oral form of a GLP-1 drug lost up to 13% of their body weight over just three months, according to results presented by drugmaker Novo Nordisk in early ...
Mechanism of action. Semaglutide is a glucagon-like peptide-1 receptor agonist. [13][14][15] The drug decreases blood sugar levels. The decrease is theorized to be caused by the mimicking of the incretin glucagon-like peptide-1 (GLP-1). [34]
Bulevirtide. Bulevirtide, sold under the brand name Hepcludex, is an antiviral medication for the treatment of chronic hepatitis D (in the presence of hepatitis B). [4] The most common side effects include raised levels of bile salts in the blood and reactions at the site of injection. [4]
Zolpidem is a nonbenzodiazepine, or Z-drug, which acts as a sedative and hypnotic. [11][20] Zolpidem is a GABA A receptor agonist of the imidazopyridine class. [11] It works by increasing GABA effects in the central nervous system by binding to GABA A receptors at the same location as benzodiazepines. [11]
When GLP-1 drugs for diabetes and weight loss, exploded onto the scene two years ago, patients scrambled to get their hands on them.GLP-1s, which include Ozempic, Wegovy, Mounjaro and Zepbound ...
Lunesta (eszopiclone) – a non-benzodiazepine hypnotic. Luvox (fluvoxamine) – an antidepressant of the SSRI class. Loxitane (loxapine) – an antipsychotic used in the treatment of mood disorders and schizophrenia. Lyrica (pregabalin) – treats nerve and muscle pain, including fibromyalgia. It can also treat seizures.
Dexanabinol (HU-211 or ETS2101 [1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210 . [ 2 ] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead as an NMDA antagonist . [ 3 ]
Zalcitabine (2′-3′-di deoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.